Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Diabetology International
Erschienen in:

05.05.2024 | Original Article

Impact of treatment cessation on incidence and progression of retinopathy in Japanese patients with type 2 diabetes mellitus: a retrospective cohort study

verfasst von: Yukiko Shinzato, Yoshiro Nakayama, Shiki Okamoto, Jasmine F. Millman, Tsugumi Uema, Ken-ichiro Honma, Atsuko Tamaki, Moriyuki Uehara, Taiki Teruya, Takamitsu Yabiku, Yohei Ishiki, Ken Yonaha, Ko-ichiro Arakaki, Moritake Higa, Hideki Koizumi, Koshi Nakamura, Michio Shimabukuro, Hiroaki Masuzaki

Erschienen in: Diabetology International | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Aims

This cohort study investigated the association between treatment cessation and incidence/progression of diabetic retinopathy (DR) in Japanese patients with type 2 diabetes mellitus (T2DM).

Materials and methods

Data were extracted from electronic medical records at the University of the Ryukyu Hospital and the Tomishiro Central Hospital of Okinawa, Japan. We enrolled 417 diabetic patients without DR (N = 281) and with nonproliferative DR (N = 136) at the baseline. Treatment cessation was defined as failing to attend outpatient clinics for at least twelve months prior to the baseline. After a median follow-up of 7 years, we compared the incidence/progression rate of DR including nonproliferative and proliferative DR between patients with and without treatment cessation and calculated the odds ratio (OR) in the treatment cessation group using a logistic regression model.

Results

The overall prevalence of treatment cessation was 13% in patients with T2DM. Characteristics of treatment cessation included relative youth (57 ± 11 years vs. 63 ± 12 years, P < 0.01). Treatment cessation was tightly associated with the incidence of DR (OR 4.20 [95% confidence interval [CI] 1.46–12.04, P < 0.01) and also incidence/progression of DR (OR 2.70 [1.28–5.69], P < 0.01), even after adjusting for age, sex, BMI, duration of T2DM, and HbA1c level.

Conclusions

By considering major confounding factors, the present study demonstrates an independent association between treatment cessation and incidence of DR in patients with T2DM, highlighting treatment cessation as an independent risk for DR in T2DM.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Wong TY, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64.PubMedPubMedCentral
2.
Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, Gardner TW, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:412–8.PubMedPubMedCentral
3.
Lin KY, Hsih WH, Lin YB, Wen CY, Chang TJ. Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig. 2021;12:1322–5.PubMedPubMedCentral
4.
Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care. 2012;35:592–6.PubMedPubMedCentral
5.
Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925–66.PubMedPubMedCentral
6.
Griffin SJ. Lost to follow-up: the problem of defaulters from diabetes clinics. Diabet Med. 1998;15(Suppl 3):14–24.
7.
Brewster S, Bartholomew J, Holt RIG, Price H. Non-attendance at diabetes outpatient appointments: a systematic review. Diabet Med. 2020;37:1427–42.PubMed
8.
Sun CA, Taylor K, Levin S, Renda SM, Han HR. Factors associated with missed appointments by adults with type 2 diabetes mellitus: a systematic review. BMJ Open Diabetes Res Care. 2021;9: e001819.PubMedPubMedCentral
9.
Masding MG, Klejdys S, MacHugh B, Gale S, Brown A, McAulay A. Non-attendance at a diabetes transitional clinic and glycaemic control. Pract Diabetes Int. 2010;27:109–10.
10.
McCarlie J, Anderson A, Collier A, Jaap A, McGettrick P, MacPherson N. Who missed routine diabetic review? Information from a district diabetes register. Pract Diabetes Int. 2002;19:283–6.
11.
Garcia Diaz E, Ramirez Medina D, Garcia Lopez A, Morera Porras OM. Determinants of adherence to hypoglycemic agents and medical visits in patients with type 2 diabetes mellitus. Endocrinol Diabetes Nutr. 2017;64:531–8.PubMed
12.
Low SK, Khoo JK, Tavintharan S, Lim SC, Sum CF. Missed appointments at a diabetes centre: not a small problem. Ann Acad Med Singapore. 2016;45:1–5.PubMed
13.
Karter AJ, Parker MM, Moffet HH, Ahmed AT, Ferrara A, Liu JY, et al. Missed appointments and poor glycemic control: an opportunity to identify high-risk diabetic patients. Med Care. 2004;42:110–5.PubMed
14.
Akhter K, Dockray S, Simmons D. Exploring factors influencing non-attendance at the diabetes clinic and service improvement strategies from patients’ perspectives. Pract Diabetes. 2012;29:113–6.
15.
Alvarez C, Saint-Pierre C, Herskovic V, Sepulveda M. Analysis of the relationship between the referral and evolution of patients with type 2 diabetes mellitus. Int J Environ Res Pub Health. 2018;15:1534.
16.
Campbell-Richards D. Exploring diabetes non-attendance: an inner London perspective. J Diabetes Nurs. 2016;20:73–8.
17.
Snow R, Fulop N. Understanding issues associated with attending a young adult diabetes clinic: A case study. Diabet Med. 2012;29:257–9.PubMedPubMedCentral
18.
Ngwenya BT, Van Zyl DG, Webb EM. Factors influencing nonattendance of clinic appointments in diabetic patients at a Gauteng hospital in 2007/2008. J Endocrinol Metab Diabetes S Africa. 2009;14:106–9.
19.
Heydarabadi AB, Mehr HM, Nouhjah S. Why rural diabetic patients do not attend for scheduled appointments: Results of a qualitative study. Diabetes Metab Syndr. 2017;11:989–95.
20.
Vijayaraghavan S, O’Shea T, Campbell-Richards D, Sudra R, Morris J, Byrne E, et al. DAWN: Diabetes Appointments via Webcam in Newham. Br J Diabetes Vasc Dis. 2015;15:123–6.
21.
Wilson SJ, Greenhalgh S. Keeping in touch with young people—where have all the DNA’ers gone? Pract Diabetes Int. 1999;16:87–8.
22.
Hardy KJ, O’Brien SV, Furlong NJ. Information given to patients before appointments and its effect on non-attendance rate. BMJ. 2001;323:1298–300.PubMedPubMedCentral
23.
Weaver KR, Talley M, Mullins M, Selleck C. Evaluating patient navigation to improve first appointment no-show rates in uninsured patients with diabetes. J Community Health Nurs. 2019;36:11–8.PubMed
24.
Horny M, Glover W, Gupte G, Saraswat A, Vimalananda V, Rosenzweig J. Patient navigation to improve diabetes outpatient care at a safety-net hospital: a retrospective cohort study. BMC Health Serv Res. 2017;17:759.PubMedPubMedCentral
25.
26.
Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Evans M, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35:1279–84.PubMedPubMedCentral
27.
Hammersley MS, Holland MR, Walford S, Thorn PA. What happens to defaulters from a diabetic clinic? Br Med J (Clin Res Ed). 1985;291:1330–2.PubMed
28.
Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Johnson JA, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.PubMedPubMedCentral
29.
Wilkinson CP, Ferris FL III, Klein RE, Lee PP, Agardh CD, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–82.PubMed
30.
Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233–44.PubMed
31.
Agardh E, Tababat-Khani P. Adopting 3-Year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes Care. 2011;34:1318–9.PubMedPubMedCentral
32.
Archibald LK, Gill GV. Diabetic clinic defaulters—who are they and why do they default? Practical Diabetes International. 1992;9:13–4.
33.
Kawasaki R, Tanaka S, Tanaka S, Yamamoto T, Sone H, Ohashi Y, et al. Japan Diabetes Complications Study Group. Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study (JDCS). Diabetologia. 2011;54:2288–94.PubMed
34.
Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Karter AJ, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the diabetes & aging study). Diabetes Care. 2019;42:416–26.PubMed
35.
Takao T, Matsuyama Y, Suka M, Yanagisawa H, Kasuga M. Analysis of the duration and extent of the legacy effect in patients with type 2 diabetes: a real-world longitudinal study. J Diabetes Complications. 2019;33:516–22.PubMed
36.
Pothen L, Balligand JL. Legacy in Cardiovascular risk factors control: from theory to future therapeutic strategies? Antioxidants. 2021;22(10):1849.
37.
Folz R, Laiteerapong N. The legacy effect in diabetes: are there long-term benefits? Diabetologia. 2021;64:2131–7.PubMedPubMedCentral
38.
Jin J, Wang X, Zhi X, Meng D. Epigenetic regulation in diabetic vascular complications. J Mol Endocrinol. 2019;63:103–15.
39.
Ceriello A. Hypothesis: the “metabolic memory”, the new challenge of diabetes. Diabetes Res Clin Pract. 2009;86:2–6.
40.
Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94:410–5.PubMed
41.
Simó R, Franch-Nadal J, Vlacho B, Real J, Amado E, Flores J, et al. Rapid reduction of HbA1c and early worsening of diabetic retinopathy: a real-world population-based study in subjects with type 2 diabetes. Diabetes Care. 2023;46:1633–9.PubMed
42.
Feldman-Billard S, Larger É, Massin P. Standards for screening and surveillance of ocular complications in people with diabetes SFD study group. Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab. 2018;44:4–14.PubMed
43.
Bain SC, Klufas MA, Ho A, Matthews DR. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review. Diabetes Obes Metab. 2019;21:454–66.PubMed
44.
Kim NH, Choi J, Kim NH, Choi KM, Baik SH, Lee J, et al. Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: a population-based study. Diabetes Metab. 2018;44:361–7.PubMed
45.
Graber AL, Davidson P, Brown AW, McRae JR, Woolridge K. Dropout and relapse during diabetes care. Diabetes Care. 1992;15:1477–83.PubMed
46.
Benoit SR, Ji M, Fleming R, Philis-Tsimikas A. Predictors of dropouts from a San Diego diabetes program: a case control study. Prev Chronic Dis. 2004;1:10.
47.
Sone H, Kawai K, Takagi H, Yamada N, Kobayashi M. Outcome of one-year of specialist care of patients with type 2 diabetes: a multi-center prospective survey. Intern Med. 2006;45:589–97.PubMed
48.
Kawahara R, Amemiya T, Yoshino M, Miyamae M, Sasamoto K. Dropout of young non-insulin-dependent diabetics from diabetes care. Diabetes Res Clin Pract. 1994;24:181–5.PubMed
Metadaten
Titel
Impact of treatment cessation on incidence and progression of retinopathy in Japanese patients with type 2 diabetes mellitus: a retrospective cohort study
verfasst von
Yukiko Shinzato
Yoshiro Nakayama
Shiki Okamoto
Jasmine F. Millman
Tsugumi Uema
Ken-ichiro Honma
Atsuko Tamaki
Moriyuki Uehara
Taiki Teruya
Takamitsu Yabiku
Yohei Ishiki
Ken Yonaha
Ko-ichiro Arakaki
Moritake Higa
Hideki Koizumi
Koshi Nakamura
Michio Shimabukuro
Hiroaki Masuzaki
Publikationsdatum
05.05.2024
Verlag
Springer Nature Singapore
Erschienen in
Diabetology International / Ausgabe 3/2024
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-024-00724-7

Weitere Artikel der Ausgabe 3/2024

A case of insulinoma misidentified as schizophrenia due to its manifestation in neuropsychiatric symptoms

  • Case Report

Advances in basic research on glucagon and alpha cells

  • Mini-Review

Incidence of overt diabetes in pregnancy among women with 50-g glucose challenge test ≥ 200 mg/dL

  • Original Article

Predictors of the effectiveness of isCGM usage in adults with type 1 diabetes mellitus: post-hoc analysis of the ISCHIA study

  • Original Article

Uric acid is associated with type 2 diabetes: data mining approaches

  • Original Article

Immune checkpoint inhibitor-related type 1 diabetes mellitus which develops long after treatment discontinuation: a case report and review of literature

  • Case Report

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Schützt das tägliche Glas Milch vor Darmkrebs?

Die Milch machts – sie bietet Frauen nach Daten einer großen Ernährungsanalyse den besten Darmkrebsschutz aller Lebensmittel, was am hohen Kalziumgehalt liegen dürfte. Am anderen Ende des Spektrums steht der Alkoholkonsum: Das Glas Wein am Abend ist eher ungünstig.

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise